Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lyell Immunopharma (LYEL) Shares Outstanding (Diluted Average) (2019 - 2025)

Lyell Immunopharma (LYEL) has disclosed Shares Outstanding (Diluted Average) for 7 consecutive years, with $17.1 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Diluted Average) rose 30.74% to $17.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $17.1 million through Dec 2025, up 30.74% year-over-year, with the annual reading at $17.1 million for FY2025, 30.74% up from the prior year.
  • Shares Outstanding (Diluted Average) hit $17.1 million in Q4 2025 for Lyell Immunopharma, down from $18.3 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $295.1 million in Q1 2025 to a low of $12.5 million in Q4 2023.
  • Historically, Shares Outstanding (Diluted Average) has averaged $140.4 million across 5 years, with a median of $187.7 million in 2021.
  • Biggest five-year swings in Shares Outstanding (Diluted Average): skyrocketed 1313.72% in 2022 and later crashed 94.92% in 2023.
  • Year by year, Shares Outstanding (Diluted Average) stood at $135.9 million in 2021, then soared by 81.79% to $247.1 million in 2022, then plummeted by 94.92% to $12.5 million in 2023, then rose by 4.18% to $13.1 million in 2024, then soared by 30.74% to $17.1 million in 2025.
  • Business Quant data shows Shares Outstanding (Diluted Average) for LYEL at $17.1 million in Q4 2025, $18.3 million in Q3 2025, and $14.8 million in Q2 2025.